Your session is about to expire
← Back to Search
EBUS-TBNA Diagnostic Procedure for Early-Stage Lung Cancer
N/A
Recruiting
Led By George A. Eapen, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patient must have proven or suspected non small cell lung cancer (NSCLC) and be clinical Stage I or IIa, according to the 7th edition staging system of the American Joint Commission on Cancer for lung cancer (T1 or T2a, N0 or N1, M0)
Patient must be > 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights
Study Summary
This trial looks at EBUS-TBNA after PET/CT to see if it can help diagnose patients with early stage NSCLC who are being evaluated for SBRT.
Who is the study for?
This trial is for adults over 18 with early-stage non-small cell lung cancer (Stage I or IIa), who haven't had chemotherapy or radiotherapy for this cancer, and are being considered for a precise type of radiation therapy called SBRT. They must have had a PET/CT scan within the last 40 days and provided written consent. Cancer survivors can join if they've been free from active disease for at least five years.Check my eligibility
What is being tested?
The study is testing how well EBUS-TBNA works in diagnosing patients after they've had a PET/CT scan. It aims to improve accuracy in detecting early-stage lung cancer among those evaluated for stereotactic body radiation therapy.See study design
What are the potential side effects?
While not explicitly listed, potential side effects of EBUS-TBNA may include discomfort at the biopsy site, minor bleeding, infection risk, and rarely complications related to sedation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My lung cancer is in the early stages (Stage I or IIa).
Select...
I am older than 18 years.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 day
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Lymphnode Staging Accuracy
Trial Design
1Treatment groups
Experimental Treatment
Group I: EBUS-TBNAExperimental Treatment1 Intervention
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,966 Previous Clinical Trials
1,804,631 Total Patients Enrolled
George A. Eapen, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
61 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are planning to get treatment at a different hospital or clinic.I am being considered for a type of radiation therapy called SBRT.I am already scheduled for standard cancer treatments other than at disease progression.My lung cancer is in the early stages (Stage I or IIa).I had a PET/CT scan within 40 days before my lung biopsy.I had cancer before, was treated with the intent to cure, and have been free of cancer for 5 years.My cancer is a type of well-differentiated neuroendocrine tumor.I am older than 18 years.I have had chemotherapy or radiotherapy for my cancer.
Research Study Groups:
This trial has the following groups:- Group 1: EBUS-TBNA
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is the enrollment phase of this clinical trial still open?
"The clinical trial in question is actively seeking out participants, as indicated on the website of clinicaltrials.gov. The study was originally listed on March 18th 2016 and has been recently updated October 4th 2022."
Answered by AI
What is the current capacity for participants in this research endeavor?
"Affirmative. On clinicaltrials.gov, it is evident that this trial has been recruiting since March 18th 2016 and was recently updated on October 4th 2022. 150 participants need to be recruited across a single medical site."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger